Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-01

AUTHORS

Rebekah White, Catherine Lee, Mitchell Anscher, Marsha Gottfried, Robert Wolff, Mary Keogan, Theodore Pappas, Herbert Hurwitz, Douglas Tyler

ABSTRACT

Background: Improved resectability is a major theoretical benefit of preoperative chemoradiation for pancreatic cancer. Since 1994, patients at Duke University Medical Center with locally advanced pancreatic cancer have been treated with multimodality preoperative therapy. The purpose of this study was to review our experience with preoperative therapy for locally advanced pancreatic cancer and determine if an aggressive neoadjuvant regimen would not only downstage these tumors pathologically but also improve the odds of complete surgical resection.Methods: The charts of 25 patients treated with neoadjuvant chemoradiation at Duke University Medical Center with biopsy-proven, locally advanced adenocarcinoma of the pancreas were reviewed. Tumors were defined as locally advanced based on radiographic or intraoperative evidence of disease that abuts the superior mesenteric artery or vein (n = 22) or involves lymph nodes that are within the proposed radiation field (n = 3). All 25 patients received external beam radiotherapy (median dose 4500 cGy) in daily fractions of 180 cGy over 5 weeks. All patients concurrently received 5-fluorouracil (FU), and many also received mitomycin C or cisplatin, or both. Patients were given a 3- to 4-week break before a restaging computed tomographic (CT) scan was performed. Three patients were not restaged: one died from metastatic disease; one was reclassified as having a neuroendocrine tumor; and one was lost to follow-up.Results: On restaging after neoadjuvant therapy, 64% of patients had stable or decreased primary tumor size. Radiographically, two patients appeared potentially resectable, and seven others developed evidence of metastatic disease. Eight patients underwent exploration, but only five could be resected. Of the five patients resected, only one had negative margins and negative lymph nodes. This patient had significant pancreatitis on initial exploration. After neoadjuvant therapy, he had a complete response radiographically, and there was no residual cancer in his resection specimen. Pathologic examination of the other resection specimens suggested that despite significant tumor fibrosis, malignant cells persist even at the periphery of the lesions.Conclusion: Although neoadjuvant chemoradiation has many theoretical advantages in managing pancreatic malignancy, true pathologic downstaging of locally advanced lesions into tumors that can be removed with negative nodes and margins appears to be a rare event with currently used therapeutic regimens. More... »

PAGES

38-45

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10434-999-0038-z

DOI

http://dx.doi.org/10.1007/s10434-999-0038-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022001684

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10030414


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibiotics, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose Fractionation, Radiation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitomycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Preoperative Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "White", 
        "givenName": "Rebekah", 
        "id": "sg:person.01264552625.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264552625.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Radiation Oncology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Radiation Oncology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Catherine", 
        "id": "sg:person.01147475467.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147475467.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Radiation Oncology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Radiation Oncology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anscher", 
        "givenName": "Mitchell", 
        "id": "sg:person.012172323537.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012172323537.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Pathology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Pathology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gottfried", 
        "givenName": "Marsha", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Medicine, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Medicine, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolff", 
        "givenName": "Robert", 
        "id": "sg:person.01133335751.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Radiology (MK), Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Radiology (MK), Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Keogan", 
        "givenName": "Mary", 
        "id": "sg:person.01220137440.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220137440.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pappas", 
        "givenName": "Theodore", 
        "id": "sg:person.01243775043.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243775043.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Medicine, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Medicine, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hurwitz", 
        "givenName": "Herbert", 
        "id": "sg:person.01242177577.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
          "id": "http://www.grid.ac/institutes/grid.26009.3d", 
          "name": [
            "Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina", 
            "Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tyler", 
        "givenName": "Douglas", 
        "id": "sg:person.07652514437.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07652514437.06"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00308636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027568603", 
          "https://doi.org/10.1007/bf00308636"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-01", 
    "datePublishedReg": "1999-01-01", 
    "description": "Background: Improved resectability is a major theoretical benefit of preoperative chemoradiation for pancreatic cancer. Since 1994, patients at Duke University Medical Center with locally advanced pancreatic cancer have been treated with multimodality preoperative therapy. The purpose of this study was to review our experience with preoperative therapy for locally advanced pancreatic cancer and determine if an aggressive neoadjuvant regimen would not only downstage these tumors pathologically but also improve the odds of complete surgical resection.Methods: The charts of 25 patients treated with neoadjuvant chemoradiation at Duke University Medical Center with biopsy-proven, locally advanced adenocarcinoma of the pancreas were reviewed. Tumors were defined as locally advanced based on radiographic or intraoperative evidence of disease that abuts the superior mesenteric artery or vein (n = 22) or involves lymph nodes that are within the proposed radiation field (n = 3). All 25 patients received external beam radiotherapy (median dose 4500 cGy) in daily fractions of 180 cGy over 5 weeks. All patients concurrently received 5-fluorouracil (FU), and many also received mitomycin C or cisplatin, or both. Patients were given a 3- to 4-week break before a restaging computed tomographic (CT) scan was performed. Three patients were not restaged: one died from metastatic disease; one was reclassified as having a neuroendocrine tumor; and one was lost to follow-up.Results: On restaging after neoadjuvant therapy, 64% of patients had stable or decreased primary tumor size. Radiographically, two patients appeared potentially resectable, and seven others developed evidence of metastatic disease. Eight patients underwent exploration, but only five could be resected. Of the five patients resected, only one had negative margins and negative lymph nodes. This patient had significant pancreatitis on initial exploration. After neoadjuvant therapy, he had a complete response radiographically, and there was no residual cancer in his resection specimen. Pathologic examination of the other resection specimens suggested that despite significant tumor fibrosis, malignant cells persist even at the periphery of the lesions.Conclusion: Although neoadjuvant chemoradiation has many theoretical advantages in managing pancreatic malignancy, true pathologic downstaging of locally advanced lesions into tumors that can be removed with negative nodes and margins appears to be a rare event with currently used therapeutic regimens.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10434-999-0038-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "Duke University Medical Center", 
      "advanced pancreatic cancer", 
      "University Medical Center", 
      "pancreatic cancer", 
      "preoperative chemoradiation", 
      "preoperative therapy", 
      "neoadjuvant chemoradiation", 
      "neoadjuvant therapy", 
      "advanced adenocarcinoma", 
      "metastatic disease", 
      "lymph nodes", 
      "Medical Center", 
      "negative lymph nodes", 
      "complete surgical resection", 
      "primary tumor size", 
      "superior mesenteric artery", 
      "external beam radiotherapy", 
      "neoadjuvant regimen", 
      "significant pancreatitis", 
      "pathologic downstaging", 
      "intraoperative evidence", 
      "surgical resection", 
      "residual cancer", 
      "complete response", 
      "mesenteric artery", 
      "negative nodes", 
      "tumor size", 
      "negative margins", 
      "resection specimen", 
      "pathologic examination", 
      "daily fractions", 
      "therapeutic regimens", 
      "neuroendocrine tumors", 
      "resection specimens", 
      "pancreatic malignancy", 
      "tomographic scan", 
      "advanced lesions", 
      "tumor fibrosis", 
      "beam radiotherapy", 
      "chemoradiation", 
      "patients", 
      "malignant cells", 
      "therapy", 
      "tumors", 
      "cancer", 
      "mitomycin C", 
      "disease", 
      "adenocarcinoma", 
      "restaging", 
      "lesions", 
      "pancreas", 
      "theoretical advantages", 
      "theoretical benefits", 
      "rare event", 
      "downstaging", 
      "resectability", 
      "regimen", 
      "resection", 
      "pancreatitis", 
      "regimens", 
      "artery", 
      "fibrosis", 
      "malignancy", 
      "radiotherapy", 
      "cisplatin", 
      "weeks", 
      "evidence", 
      "odds", 
      "vein", 
      "scans", 
      "center", 
      "examination", 
      "cells", 
      "charts", 
      "response", 
      "initial exploration", 
      "margin", 
      "nodes", 
      "study", 
      "specimens", 
      "benefits", 
      "events", 
      "periphery", 
      "experience", 
      "purpose", 
      "specimen", 
      "exploration", 
      "fraction", 
      "breaks", 
      "size", 
      "radiation field", 
      "advantages", 
      "field"
    ], 
    "name": "Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas", 
    "pagination": "38-45", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022001684"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10434-999-0038-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10030414"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10434-999-0038-z", 
      "https://app.dimensions.ai/details/publication/pub.1022001684"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_327.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10434-999-0038-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10434-999-0038-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10434-999-0038-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10434-999-0038-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10434-999-0038-z'


 

This table displays all metadata directly associated to this object as RDF triples.

301 TRIPLES      21 PREDICATES      140 URIs      131 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10434-999-0038-z schema:about N0c592e27d26a4666b1c480fd4ed75bbe
2 N1799d648771643698adde73fbf1e4c51
3 N191b8191ffa1400a9dfd3531015994a3
4 N298b6d8064e34ca6bb5ab9c76f0c5c4c
5 N2a8597a151a7420a8acafa07a08ebb34
6 N2fb056960ab74606a97e6aed75dd0a73
7 N35fb4dce2d9a47149eda3c270ceaec74
8 N3d8a354ba34840c18ba8f5c16b2923f3
9 N61422e53c5e94cef8b8add886749f15c
10 N628d81f300bf47d0bafb276607c830a6
11 N6423965abdda4761a3fca9ca2e76a257
12 N7a1b232e3f1246829696f0c41c4a9bea
13 N802559679732493588c0bc01c68cc2a7
14 Nab76100bb9b249979f1056a6811f93a0
15 Nb0cb5e8562904508a9033f611913ada5
16 Nb72643565d66485aa11cd36dbcd590aa
17 Nb90fb15cd249438dbee02603b0927137
18 Nc27e275a622c42039de63f4d13630f5f
19 Ne0233df93efe4bbfbef9f1a258bc0f92
20 Ne0d7abde997b43a5a2d91f458a56ed63
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author Ne3e671fd01144c18b5e736d1bfa70bfb
24 schema:citation sg:pub.10.1007/bf00308636
25 schema:datePublished 1999-01
26 schema:datePublishedReg 1999-01-01
27 schema:description Background: Improved resectability is a major theoretical benefit of preoperative chemoradiation for pancreatic cancer. Since 1994, patients at Duke University Medical Center with locally advanced pancreatic cancer have been treated with multimodality preoperative therapy. The purpose of this study was to review our experience with preoperative therapy for locally advanced pancreatic cancer and determine if an aggressive neoadjuvant regimen would not only downstage these tumors pathologically but also improve the odds of complete surgical resection.Methods: The charts of 25 patients treated with neoadjuvant chemoradiation at Duke University Medical Center with biopsy-proven, locally advanced adenocarcinoma of the pancreas were reviewed. Tumors were defined as locally advanced based on radiographic or intraoperative evidence of disease that abuts the superior mesenteric artery or vein (n = 22) or involves lymph nodes that are within the proposed radiation field (n = 3). All 25 patients received external beam radiotherapy (median dose 4500 cGy) in daily fractions of 180 cGy over 5 weeks. All patients concurrently received 5-fluorouracil (FU), and many also received mitomycin C or cisplatin, or both. Patients were given a 3- to 4-week break before a restaging computed tomographic (CT) scan was performed. Three patients were not restaged: one died from metastatic disease; one was reclassified as having a neuroendocrine tumor; and one was lost to follow-up.Results: On restaging after neoadjuvant therapy, 64% of patients had stable or decreased primary tumor size. Radiographically, two patients appeared potentially resectable, and seven others developed evidence of metastatic disease. Eight patients underwent exploration, but only five could be resected. Of the five patients resected, only one had negative margins and negative lymph nodes. This patient had significant pancreatitis on initial exploration. After neoadjuvant therapy, he had a complete response radiographically, and there was no residual cancer in his resection specimen. Pathologic examination of the other resection specimens suggested that despite significant tumor fibrosis, malignant cells persist even at the periphery of the lesions.Conclusion: Although neoadjuvant chemoradiation has many theoretical advantages in managing pancreatic malignancy, true pathologic downstaging of locally advanced lesions into tumors that can be removed with negative nodes and margins appears to be a rare event with currently used therapeutic regimens.
28 schema:genre article
29 schema:isAccessibleForFree false
30 schema:isPartOf N39389348d194490da4d7e8163a19c3c6
31 Ncd1384f9faa44fccbfe27370c7abdc5c
32 sg:journal.1105545
33 schema:keywords Duke University Medical Center
34 Medical Center
35 University Medical Center
36 adenocarcinoma
37 advanced adenocarcinoma
38 advanced lesions
39 advanced pancreatic cancer
40 advantages
41 artery
42 beam radiotherapy
43 benefits
44 breaks
45 cancer
46 cells
47 center
48 charts
49 chemoradiation
50 cisplatin
51 complete response
52 complete surgical resection
53 daily fractions
54 disease
55 downstaging
56 events
57 evidence
58 examination
59 experience
60 exploration
61 external beam radiotherapy
62 fibrosis
63 field
64 fraction
65 initial exploration
66 intraoperative evidence
67 lesions
68 lymph nodes
69 malignancy
70 malignant cells
71 margin
72 mesenteric artery
73 metastatic disease
74 mitomycin C
75 negative lymph nodes
76 negative margins
77 negative nodes
78 neoadjuvant chemoradiation
79 neoadjuvant regimen
80 neoadjuvant therapy
81 neuroendocrine tumors
82 nodes
83 odds
84 pancreas
85 pancreatic cancer
86 pancreatic malignancy
87 pancreatitis
88 pathologic downstaging
89 pathologic examination
90 patients
91 periphery
92 preoperative chemoradiation
93 preoperative therapy
94 primary tumor size
95 purpose
96 radiation field
97 radiotherapy
98 rare event
99 regimen
100 regimens
101 resectability
102 resection
103 resection specimen
104 resection specimens
105 residual cancer
106 response
107 restaging
108 scans
109 significant pancreatitis
110 size
111 specimen
112 specimens
113 study
114 superior mesenteric artery
115 surgical resection
116 theoretical advantages
117 theoretical benefits
118 therapeutic regimens
119 therapy
120 tomographic scan
121 tumor fibrosis
122 tumor size
123 tumors
124 vein
125 weeks
126 schema:name Preoperative Chemoradiation for Patients With Locally Advanced Adenocarcinoma of the Pancreas
127 schema:pagination 38-45
128 schema:productId N279559eb699940de8dee2205ffc0fbae
129 N607aa907d9d1490ebd17a151984e138a
130 Nf1797e1ad5e54705a813dcbb48f5bee2
131 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022001684
132 https://doi.org/10.1007/s10434-999-0038-z
133 schema:sdDatePublished 2022-08-04T16:53
134 schema:sdLicense https://scigraph.springernature.com/explorer/license/
135 schema:sdPublisher N71115c18bda14b31880ef98e462ecf45
136 schema:url https://doi.org/10.1007/s10434-999-0038-z
137 sgo:license sg:explorer/license/
138 sgo:sdDataset articles
139 rdf:type schema:ScholarlyArticle
140 N0c592e27d26a4666b1c480fd4ed75bbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Pancreatectomy
142 rdf:type schema:DefinedTerm
143 N1799d648771643698adde73fbf1e4c51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Middle Aged
145 rdf:type schema:DefinedTerm
146 N191b8191ffa1400a9dfd3531015994a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antimetabolites, Antineoplastic
148 rdf:type schema:DefinedTerm
149 N279559eb699940de8dee2205ffc0fbae schema:name dimensions_id
150 schema:value pub.1022001684
151 rdf:type schema:PropertyValue
152 N298b6d8064e34ca6bb5ab9c76f0c5c4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Pancreatic Neoplasms
154 rdf:type schema:DefinedTerm
155 N2a8597a151a7420a8acafa07a08ebb34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Treatment Outcome
157 rdf:type schema:DefinedTerm
158 N2c24c9667b2a41aa9cb080f1c0ea6d83 rdf:first sg:person.07652514437.06
159 rdf:rest rdf:nil
160 N2fb056960ab74606a97e6aed75dd0a73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Antineoplastic Combined Chemotherapy Protocols
162 rdf:type schema:DefinedTerm
163 N2fb19d80466441069fd06c74be05e152 rdf:first sg:person.01242177577.68
164 rdf:rest N2c24c9667b2a41aa9cb080f1c0ea6d83
165 N35fb4dce2d9a47149eda3c270ceaec74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Preoperative Care
167 rdf:type schema:DefinedTerm
168 N39389348d194490da4d7e8163a19c3c6 schema:volumeNumber 6
169 rdf:type schema:PublicationVolume
170 N3d8a354ba34840c18ba8f5c16b2923f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Chemotherapy, Adjuvant
172 rdf:type schema:DefinedTerm
173 N607aa907d9d1490ebd17a151984e138a schema:name doi
174 schema:value 10.1007/s10434-999-0038-z
175 rdf:type schema:PropertyValue
176 N61422e53c5e94cef8b8add886749f15c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Mitomycin
178 rdf:type schema:DefinedTerm
179 N628d81f300bf47d0bafb276607c830a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Cisplatin
181 rdf:type schema:DefinedTerm
182 N6423965abdda4761a3fca9ca2e76a257 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Humans
184 rdf:type schema:DefinedTerm
185 N71115c18bda14b31880ef98e462ecf45 schema:name Springer Nature - SN SciGraph project
186 rdf:type schema:Organization
187 N7a1b232e3f1246829696f0c41c4a9bea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Adenocarcinoma
189 rdf:type schema:DefinedTerm
190 N802559679732493588c0bc01c68cc2a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Dose Fractionation, Radiation
192 rdf:type schema:DefinedTerm
193 N8d3e48f4c01b4cc484ce1cd38fee4213 rdf:first sg:person.01133335751.97
194 rdf:rest Nfb68f402a1d548b3b2b887a5c8da0722
195 N97bcc9aa4a6048f891b6cfae51a9ba38 rdf:first N9c64fdf50dd44254b2d4efbe51ed48c6
196 rdf:rest N8d3e48f4c01b4cc484ce1cd38fee4213
197 N9c64fdf50dd44254b2d4efbe51ed48c6 schema:affiliation grid-institutes:grid.26009.3d
198 schema:familyName Gottfried
199 schema:givenName Marsha
200 rdf:type schema:Person
201 Nab76100bb9b249979f1056a6811f93a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Antibiotics, Antineoplastic
203 rdf:type schema:DefinedTerm
204 Nb0cb5e8562904508a9033f611913ada5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Radiotherapy, Adjuvant
206 rdf:type schema:DefinedTerm
207 Nb72643565d66485aa11cd36dbcd590aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Fluorouracil
209 rdf:type schema:DefinedTerm
210 Nb90fb15cd249438dbee02603b0927137 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Aged
212 rdf:type schema:DefinedTerm
213 Nbf6fa52038ef47fa97ec97cb4b2cab18 rdf:first sg:person.01147475467.35
214 rdf:rest Necfe71d66d6c4f49b4e5e04719314c87
215 Nc27e275a622c42039de63f4d13630f5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Radiotherapy
217 rdf:type schema:DefinedTerm
218 Ncd1384f9faa44fccbfe27370c7abdc5c schema:issueNumber 1
219 rdf:type schema:PublicationIssue
220 Nd9c301d7437b422c90a15c8bcd83e03a rdf:first sg:person.01243775043.21
221 rdf:rest N2fb19d80466441069fd06c74be05e152
222 Ne0233df93efe4bbfbef9f1a258bc0f92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Male
224 rdf:type schema:DefinedTerm
225 Ne0d7abde997b43a5a2d91f458a56ed63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Female
227 rdf:type schema:DefinedTerm
228 Ne3e671fd01144c18b5e736d1bfa70bfb rdf:first sg:person.01264552625.69
229 rdf:rest Nbf6fa52038ef47fa97ec97cb4b2cab18
230 Necfe71d66d6c4f49b4e5e04719314c87 rdf:first sg:person.012172323537.04
231 rdf:rest N97bcc9aa4a6048f891b6cfae51a9ba38
232 Nf1797e1ad5e54705a813dcbb48f5bee2 schema:name pubmed_id
233 schema:value 10030414
234 rdf:type schema:PropertyValue
235 Nfb68f402a1d548b3b2b887a5c8da0722 rdf:first sg:person.01220137440.77
236 rdf:rest Nd9c301d7437b422c90a15c8bcd83e03a
237 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
238 schema:name Medical and Health Sciences
239 rdf:type schema:DefinedTerm
240 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
241 schema:name Oncology and Carcinogenesis
242 rdf:type schema:DefinedTerm
243 sg:journal.1105545 schema:issn 1068-9265
244 1534-4681
245 schema:name Annals of Surgical Oncology
246 schema:publisher Springer Nature
247 rdf:type schema:Periodical
248 sg:person.01133335751.97 schema:affiliation grid-institutes:grid.26009.3d
249 schema:familyName Wolff
250 schema:givenName Robert
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133335751.97
252 rdf:type schema:Person
253 sg:person.01147475467.35 schema:affiliation grid-institutes:grid.26009.3d
254 schema:familyName Lee
255 schema:givenName Catherine
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147475467.35
257 rdf:type schema:Person
258 sg:person.012172323537.04 schema:affiliation grid-institutes:grid.26009.3d
259 schema:familyName Anscher
260 schema:givenName Mitchell
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012172323537.04
262 rdf:type schema:Person
263 sg:person.01220137440.77 schema:affiliation grid-institutes:grid.26009.3d
264 schema:familyName Keogan
265 schema:givenName Mary
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01220137440.77
267 rdf:type schema:Person
268 sg:person.01242177577.68 schema:affiliation grid-institutes:grid.26009.3d
269 schema:familyName Hurwitz
270 schema:givenName Herbert
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68
272 rdf:type schema:Person
273 sg:person.01243775043.21 schema:affiliation grid-institutes:grid.26009.3d
274 schema:familyName Pappas
275 schema:givenName Theodore
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243775043.21
277 rdf:type schema:Person
278 sg:person.01264552625.69 schema:affiliation grid-institutes:grid.26009.3d
279 schema:familyName White
280 schema:givenName Rebekah
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264552625.69
282 rdf:type schema:Person
283 sg:person.07652514437.06 schema:affiliation grid-institutes:grid.26009.3d
284 schema:familyName Tyler
285 schema:givenName Douglas
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07652514437.06
287 rdf:type schema:Person
288 sg:pub.10.1007/bf00308636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027568603
289 https://doi.org/10.1007/bf00308636
290 rdf:type schema:CreativeWork
291 grid-institutes:grid.26009.3d schema:alternateName Departments of Medicine, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
292 Departments of Pathology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
293 Departments of Radiation Oncology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
294 Departments of Radiology (MK), Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
295 Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
296 schema:name Departments of Medicine, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
297 Departments of Pathology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
298 Departments of Radiation Oncology, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
299 Departments of Radiology (MK), Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
300 Departments of Surgery, Duke University Medical Center, Box 3118, 27710, Durham, North Carolina
301 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...